Current treatment options in patients with mastocytosis: status in 2015 and future perspectives (Q38370943)

2 September 2017

1 reference

title

Current treatment options in patients with mastocytosis: status in 2015 and future perspectives (English)

1 reference

2 September 2017

3

1 reference

2 September 2017

Cem Akin

2

0 references

Peter Valent

object named as

Peter Valent

series ordinal

4

0 references

author name string

Michel Arock

series ordinal

1

1 reference

2 September 2017

26 March 2015

1 reference

European Journal of Haematology

2 September 2017

1 reference

2 September 2017

94

1 reference

2 September 2017

6

1 reference

2 September 2017

474-490

1 reference

The riddle of the mast cell: kit(CD117)-ligand as the missing link?

2 September 2017

1 reference

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.

21 January 2018

1 reference

Primary mast cell disorders in children

21 January 2018

1 reference

Diagnosis, progression patterns and prognostication in mastocytosis

21 January 2018

1 reference

Gastrointestinal manifestations of systemic mastocytosis

21 January 2018

1 reference

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review

21 January 2018

1 reference

How I treat patients with advanced systemic mastocytosis.

21 January 2018

1 reference

Gastrointestinal manifestations in mastocytosis: a study of 83 patients.

21 January 2018

1 reference

Bone involvement and osteoporosis in mastocytosis.

21 January 2018

1 reference

Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal

21 January 2018

1 reference

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

21 January 2018

1 reference

Diagnostic criteria and classification of mastocytosis: a consensus proposal

21 January 2018

1 reference

Diagnostic criteria and classification of mastocytosis in 2014.

21 January 2018

1 reference

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria

21 January 2018

1 reference

Molecular defects in mastocytosis: KIT and beyond KIT.

21 January 2018

1 reference

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.

21 January 2018

1 reference

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

21 January 2018

1 reference

Comprehensive mutational profiling in advanced systemic mastocytosis

21 January 2018

1 reference

Cutaneous mastocytosis: a review focusing on the pediatric population

21 January 2018

1 reference

Treatment strategies in mastocytosis

21 January 2018

1 reference

Mast cells and mastocytosis

21 January 2018

1 reference

21 January 2018

1 reference

Mast cell mediators in allergic inflammation and mastocytosis

21 January 2018

1 reference

Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis.

21 January 2018

1 reference

Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells

21 January 2018

1 reference

Interleukin-31: a novel diagnostic marker of allergic diseases.

21 January 2018

1 reference

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal

21 January 2018

1 reference

Anaesthesia in patients with mastocytosis

21 January 2018

1 reference

Current options in the treatment of mast cell mediator-related symptoms in mastocytosis

21 January 2018

1 reference

Mastocytosis: current treatment concepts

21 January 2018

1 reference

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

21 January 2018

1 reference

Update on rupatadine in the management of allergic disorders

21 January 2018

1 reference

Mastocytosis and Hymenoptera venom allergy

21 January 2018

1 reference

Anaphylaxis: Recent advances in assessment and treatment

21 January 2018

1 reference

Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis.

21 January 2018

1 reference

Molecular mechanisms of glucocorticoid action in mast cells

21 January 2018

1 reference

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

21 January 2018

1 reference

The actual role of sodium cromoglycate in the treatment of asthma--a critical review

21 January 2018

1 reference

Cromolyn sodium in the management of systemic mastocytosis

21 January 2018

1 reference

Adverse reactions to cromolyn sodium: patient report and review of the literature

21 January 2018

1 reference

Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production

21 January 2018

1 reference

Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report

21 January 2018

1 reference

Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.

21 January 2018

1 reference

Denosumab for the treatment of osteoporosis

21 January 2018

1 reference

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

21 January 2018

1 reference

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

21 January 2018

1 reference

Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients

21 January 2018

1 reference

Interferon-α treatment in systemic mastocytosis

21 January 2018

1 reference

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

21 January 2018

1 reference

Treatment of systemic mast-cell disease with cladribine

21 January 2018

1 reference

Cladribine therapy for systemic mastocytosis.

21 January 2018

1 reference

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders

21 January 2018

1 reference

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

21 January 2018

1 reference

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases

21 January 2018

1 reference

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation

21 January 2018

1 reference

Masitinib is safe and effective for the treatment of canine mast cell tumors

21 January 2018

1 reference

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study

21 January 2018

1 reference

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.

21 January 2018

1 reference

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

21 January 2018

1 reference

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V

21 January 2018

1 reference

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

21 January 2018

1 reference

Dasatinib therapy for systemic mastocytosis: four cases

21 January 2018

1 reference

21 January 2018

1 reference

Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells

21 January 2018

1 reference

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib

21 January 2018

1 reference

Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations

21 January 2018

1 reference

Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling

21 January 2018

1 reference

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

21 January 2018

1 reference

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.

21 January 2018

1 reference

Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis

21 January 2018

1 reference

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

21 January 2018

1 reference

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

21 January 2018

1 reference

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

21 January 2018

1 reference

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

21 January 2018

1 reference

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal

21 January 2018

1 reference

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

21 January 2018

1 reference

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

21 January 2018

1 reference

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

21 January 2018

1 reference

The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis

21 January 2018

1 reference

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

21 January 2018

1 reference

Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms.

21 January 2018

1 reference

CD52 is a molecular target in advanced systemic mastocytosis.

21 January 2018

1 reference

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

21 January 2018

1 reference

CD30 in systemic mastocytosis.

21 January 2018

1 reference

Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

21 January 2018

1 reference

Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.

21 January 2018

1 reference

Systemic mastocytosis and bone involvement in a cohort of 75 patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EJH.12544

1 reference

2 September 2017

1 reference

PubMed ID

25753531